Drug intelligence / Profile preview

IC-100

Development stage: Preclinical
Lead developer: Astellas Pharma
Modality: Gene Therapies

Overview

IC-100 is a preclinical gene therapy candidate developed by IVERIC bio (now a wholly-owned subsidiary of Astellas Pharma) for the treatment of Leber congenital amaurosis type 10 (LCA10). LCA10 is an inherited retinal disease caused by mutations in the CEP290 gene. IC-100 is an adeno-associated virus (AAV) minigene therapy designed to address these genetic mutations. The program originated from an exclusive global license agreement with the University of Massachusetts.

Targets

PYCARD (Apoptosis-associated speck-like protein containing a CARD)CEP290 (Centrosomal protein 290)

Beyond the preview

Go deeper on IC-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC-100.